SN50
Based on 45 publication(s) in Google Scholar
SN50 is a cell permeable inhibitor of NF-κB translocation.
For research use only. We do not sell to patients.
- Purity: 99.70%
- CAS No.: 213546-53-3
- Formula: C129H230N36O29S
- Molecular Weight:2781.50
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SN50
More- Acta Pharm Sin B. 2021 Jan;11(1):71-88. [Abstract]
- Cell Rep Med. 2024 May 16:101580. [Abstract]
- Engineering. 14 October 2022.
- Cell Death Discov. 2021 Jun 25;7(1):159. [Abstract]
- Int J Biol Macromol. 2024 Nov 29:138238. [Abstract]
- Mol Ther Oncolytics. 2021 Feb 17;20:499-507. [Abstract]
- EMBO Mol Med. 2023 Jan 11;15(1):e16373. [Abstract]
- Cell Rep. 2024 Mar 21;43(4):113980. [Abstract]
- Inflamm Regen. 2022 Aug 2;42(1):24. [Abstract]
- Brain Behav Immun. 2025 Mar 31:S0889-1591(25)00122-9. [Abstract]
- Int J Oncol. 2018 Nov;53(5):2102-2110. [Abstract]
- Front Immunol. 2018 Jun 5:9:1225. [Abstract]
- CNS Neurosci Ther. 2021 May;27(5):552-563. [Abstract]
- CNS Neurosci Ther. 2020 Jun 12;26(10):1045-1057. [Abstract]
- CNS Neurosci Ther. 2019 Sep;25(9):911-921. [Abstract]
- Biochem Pharmacol. 2025 Jun:236:116857. [Abstract]
- Cancer Gene Ther. 2021 Apr;28(3-4):307-320. [Abstract]
- Life Sci. 2019 May 1;224:212-221. [Abstract]
- Mol Cancer Res. 2026 Feb 9. [Abstract]
- Commun Biol. 2025 Dec 2;9(1):27. [Abstract]
- J Affect Disord. 2025 Aug 9:391:120048. [Abstract]
- Clin Epigenetics. 2023 Jan 23;15(1):12. [Abstract]
- Neurochem Int. 2022 Jan:152:105221. [Abstract]
- Front Pharmacol. 2021 Nov 8:12:772504. [Abstract]
- Inflammation. 2019 Feb;42(1):319-330. [Abstract]
- Mol Med Rep. 2019 Nov;20(5):4045-4258. [Abstract]
- Sci Rep. 2025 Mar 28;15(1):10772. [Abstract]
- Mediators Inflamm. 2021 Dec 21:2021:9993971. [Abstract]
- J Cell Mol Med. 2021 Jun;25(12):5753-5768. [Abstract]
- J Cell Mol Med. 2020 Jul;24(13):7637-7651. [Abstract]
- Neurochem Res. 2026 Apr 1;51(2):129. [Abstract]
- iScience. 2024 Jan 11;27(2):108857. [Abstract]
- Fish Shellfish Immunol. 2022 Sep:128:38-49. [Abstract]
- J Neurotrauma. 2025 May;42(9-10):814-831. [Abstract]
- Mol Immunol. 2018 Nov:103:133-143. [Abstract]
- Stem Cells Int. 2022 Sep 12;2022:5670403. [Abstract]
- Infect Immun. 2025 Aug 12;93(8):e0015825. [Abstract]
- Mol Cell Endocrinol. 2020 Jan 15;500:110641. [Abstract]
- Mol Biotechnol. 2025 May;67(5):2035-2045. [Abstract]
- J Immunol Res. 2018 Sep 12:2018:6285813. [Abstract]
- PLoS One. 2024 Jan 2;19(1):e0294514. [Abstract]
- Exp Ther Med. 2021 Sep;22(3):1003. [Abstract]
- Cardiovasc Pathol. 2019 Jul-Aug:41:11-17. [Abstract]
- Bioengineered. 2022 Mar;13(3):6866-6879. [Abstract]
- Aging (Albany NY). 2020 Jun 22;12(12):11781-11793. [Abstract]
Customer Validation & Images
-
WB
-
WB
Biological Activity
|
NF-κB |
Pretreatment with SN50 results in a significant reduction in amount of PI-positive cells at 12, 24, and 48 h time-point post TBI compared with vehicle-treated groups[1]. Topical SN50 suppresses nuclear factor-κB activation in local cells and reduces the incidence of epithelial defects/ulceration in healing corneas. Myofibroblast generation, macrophage invasion, activity of matrix metalloproteinases, basement membrane destruction, and expression of cytokines are all decreased in treated corneas compared with controls[2]. Treating the human gastric cancer cells SGC7901 with SN50 could significantly enhance the effects of LY294002 on inducing cell death after 24 h[3]. SN50 can inhibit translocation of NF-kB and production of inflammatory cytokines that are implicated in lipopolysaccharide (LPS)-induced lung injury[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 213546-53-3
-
Appearance Solid
-
Molecular Weight 2781.50
-
Formula C129H230N36O29S
-
Color White to off-white
-
Sequence
Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro
-
Sequence Shortening
AAVALLPAVLLALLAPVQRKRQKLMP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (45)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
Activated PKB/GSK-3 β synergizes with PKC- δ signaling in attenuating myocardial ischemia/reperfusion injury via potentiation of NRF2 activity: Therapeutic efficacy of dihydrotanshinone-I. [Abstract]2021 Jan;11(1):71-88. PMID: 33532181 -
Cell Rep Med
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. [Abstract]2024 May 16:101580. PMID: 38776913 -
-
Cell Death Discov
NF-κB is involved in the regulation of autophagy in mutant p53 cells in response to ionizing radiation. [Abstract]2021 Jun 25;7(1):159. PMID: 34226514 -
Int J Biol Macromol
Inhibition of lncEPS by TLR4/NF-κB pathway induces ventilator-induced lung injury by decreasing its binding to and upregulating Hspa5. [Abstract]2024 Nov 29:138238. PMID: 39617220 -
Mol Ther Oncolytics
PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer. [Abstract]2021 Feb 17;20:499-507. PMID: 33738336 -
EMBO Mol Med
PGF2α facilitates pathological retinal angiogenesis by modulating endothelial FOS-driven ELR+ CXC chemokine expression. [Abstract]2023 Jan 11;15(1):e16373. PMID: 36511116 -
Cell Rep
Matrilin-3 supports neuroprotection in ischemic stroke by suppressing astrocyte-mediated neuroinflammation. [Abstract]2024 Mar 21;43(4):113980. PMID: 38520693 -
Inflamm Regen
Diet-induced obesity impairs spermatogenesis: the critical role of NLRP3 in Sertoli cells. [Abstract]2022 Aug 2;42(1):24. PMID: 35915511 -
Brain Behav Immun
TLR9 in satellite glial cells promotes paclitaxel-induced neuropathic pain by reducing Kir4.1 transcription through histone methylation activation. [Abstract]2025 Mar 31:S0889-1591(25)00122-9. PMID: 40174869 -
Int J Oncol
ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NF‑κB signaling pathway. [Abstract]2018 Nov;53(5):2102-2110. PMID: 30106136 -
Front Immunol
Stimulator of Interferon Genes Promotes Host Resistance Against Pseudomonas aeruginosa Keratitis. [Abstract]2018 Jun 5:9:1225. PMID: 29922287 -
CNS Neurosci Ther
2021 May;27(5):552-563. PMID: 33460245 -
CNS Neurosci Ther
Hypertonic saline mediates the NLRP3/IL-1β signaling axis in microglia to alleviate ischemic blood-brain barrier permeability by downregulating astrocyte-derived VEGF in rats. [Abstract]2020 Jun 12;26(10):1045-1057. PMID: 32529750 -
CNS Neurosci Ther
Olanzapine induced autophagy through suppression of NF-κB activation in human glioma cells. [Abstract]2019 Sep;25(9):911-921. PMID: 30955240 -
Biochem Pharmacol
The SGLT2 inhibitor dapagliflozin suppresses endothelial cell pyroptosis mediated by the NF-κB/NLRP3 pathway through downregulation of CTSB. [Abstract]2025 Jun:236:116857. PMID: 40058708 -
Cancer Gene Ther
Silencing of long non-coding RNA XIST represses gastric cancer progression through blocking NFκB pathway via inhibiting HNF4A-mediated transcription of EPHA1. [Abstract]2021 Apr;28(3-4):307-320. PMID: 33199830 -
Life Sci
Abnormality of hepatic triglyceride metabolism in ApcMin/+ mice with colon cancer cachexia. [Abstract]2019 May 1;224:212-221. PMID: 31002917 -
Mol Cancer Res
UBE2B Drives NF-κB Signaling and Gastric Cancer Progression through BIRC2-Mediated K63-Linked Ubiquitination of TRAF1. [Abstract]2026 Feb 9. PMID: 41661096 -
Commun Biol
Pentraxin 3 ameliorates glucocorticoid-induced osteonecrosis of the femoral head via TLR4/NF-κB/FGF21 signaling axis. [Abstract]2025 Dec 2;9(1):27. PMID: 41331332 -
J Affect Disord
Antidepressant in treating myocardial infarction complicated with depression via 5-HT/inflammation from heart to brain. [Abstract]2025 Aug 9:391:120048. PMID: 40789439 -
Clin Epigenetics
Azithromycin attenuates wheezing after pulmonary inflammation through inhibiting histone H3K27me3 hypermethylation mediated by EZH2. [Abstract]2023 Jan 23;15(1):12. PMID: 36691058 -
Neurochem Int
Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinson's disease via inhibiting p38MAPK/NF-κB signaling pathway. [Abstract]2022 Jan:152:105221. PMID: 34780806 -
Front Pharmacol
Pharmacological Basis for Use of a Novel Compound in Hyperuricemia: Anti-Hyperuricemic and Anti-Inflammatory Effects. [Abstract]2021 Nov 8:12:772504. PMID: 34819865 -
Inflammation
GDF11 Antagonizes Psoriasis-like Skin Inflammation via Suppression of NF-κB Signaling Pathway. [Abstract]2019 Feb;42(1):319-330. PMID: 30259241
SN50 purchased from MedChemExpress. Usage Cited in: Inflammation. 2019 Feb;42(1):319-330. [Abstract]
The protein expression of iNOS and COX-2 in TNF-α stimulated RAW264.7 cells with selectively co-cultured with SN50 and SiGDF11, as determined by western blot.
-
Mol Med Rep
Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor‑κB signaling pathway. [Abstract]2019 Nov;20(5):4045-4258. PMID: 31485630 -
Sci Rep
PKM2 accelerated the progression of chronic fatigue syndrome via promoting the H4K12la/ NF-κB induced neuroinflammation and mitochondrial damage. [Abstract]2025 Mar 28;15(1):10772. PMID: 40155479 -
Mediators Inflamm
Extracellular HMGB1 Induced Glomerular Endothelial Cell Injury via TLR4/MyD88 Signaling Pathway in Lupus Nephritis. [Abstract]2021 Dec 21:2021:9993971. PMID: 34970076 -
J Cell Mol Med
Qianliexin capsule exerts anti-inflammatory activity in chronic non-bacterial prostatitis and benign prostatic hyperplasia via NF-κB and inflammasome. [Abstract]2021 Jun;25(12):5753-5768. PMID: 33982874 -
J Cell Mol Med
SNHG16/miR-605-3p/TRAF6/NF-κB feedback loop regulates hepatocellular carcinoma metastasis. [Abstract]2020 Jul;24(13):7637-7651. PMID: 32436333 -
Neurochem Res
Curcumin and Glycyrrhiza glabra Synergistically Attenuate Alzheimer's Pathology via TLR4/NF-κB-Mediated Anti-inflammatory and Redox Modulation in a D-Gal/Sodium Nitrite-Induced Mouse Model. [Abstract]2026 Apr 1;51(2):129. PMID: 41920384 -
iScience
Whitening of brown adipose tissue inhibits osteogenic differentiation via secretion of S100A8/A9. [Abstract]2024 Jan 11;27(2):108857. PMID: 38303710 -
Fish Shellfish Immunol
NF-κB-coupled IL17 mediates inflammatory signaling and intestinal inflammation in Artemia sinica. [Abstract]2022 Sep:128:38-49. PMID: 35917889 -
J Neurotrauma
Attenuation of Blood-Brain Barrier Disruption in Traumatic Brain Injury via Inhibition of NKCC1 Cotransporter: Insights into the NF-κB/NLRP3 Signaling Pathway. [Abstract]2025 May;42(9-10):814-831. PMID: 39879999 -
Mol Immunol
CD8+iTregs attenuate glomerular endothelial cell injury in lupus-prone mice through blocking the activation of p38 MAPK and NF-κB. [Abstract]2018 Nov:103:133-143. PMID: 30268079 -
Stem Cells Int
Glycogen Synthase Kinase 3 β inhibits BMSCs Chondrogenesis in Inflammation via the Cross-Reaction between NF- κ B and β-Catenin in the Nucleus. [Abstract]2022 Sep 12;2022:5670403. PMID: 36132167 -
Infect Immun
Rickettsia heilongjiangensis suppresses RIPK1 kinase-mediated host cell death during the infection. [Abstract]2025 Aug 12;93(8):e0015825. PMID: 40607949 -
Mol Cell Endocrinol
The NF-κB/miR-425-5p/MCT4 axis: A novel insight into diabetes-induced endothelial dysfunction. [Abstract]2020 Jan 15;500:110641. PMID: 31711985
SN50 purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2020 Jan 15;500:110641. [Abstract]
HUVECs are treated with HG (30 mM), IL-1β (10 ng/mL) and/or SN50 (50 μg/mL), an NF-κB inhibitor. After treatment for 48 h, the protein levels of NF-κB p65 and p-NF-κB p65 in the nucleus of HUVECs were determined using Western blotting. Histone H3 was used for normalization.
-
Mol Biotechnol
Improving Intestinal Barrier Function in Sepsis by Partially Hydrolysed Guar Gum via the Suppression of the NF-κB/MLCK Pathway. [Abstract]2025 May;67(5):2035-2045. PMID: 38789715 -
J Immunol Res
Serum and Ectopic Endometrium from Women with Endometriosis Modulate Macrophage M1/M2 Polarization via the Smad2/Smad3 Pathway. [Abstract]2018 Sep 12:2018:6285813. PMID: 30276219 -
PLoS One
Cathepsin B aggravates atherosclerosis in ApoE-deficient mice by modulating vascular smooth muscle cell pyroptosis through NF-κB / NLRP3 signaling pathway. [Abstract]2024 Jan 2;19(1):e0294514. PMID: 38165884 -
Exp Ther Med
Protein arginine methyltransferase 5 mediates THP-1-derived macrophage activation dependent on NF-κB in endometriosis. [Abstract]2021 Sep;22(3):1003. PMID: 34345285 -
Cardiovasc Pathol
APOC3 promotes TNF-α-induced expression of JAM-1 in endothelial cell via PI3K-IKK2-p65 pathway. [Abstract]2019 Jul-Aug:41:11-17. PMID: 31004933 -
Bioengineered
Cyclin D1 mediated by the nuclear translocation of nuclear factor kappa B exerts an oncogenic role in lung cancer. [Abstract]2022 Mar;13(3):6866-6879. PMID: 35246017 -
Aging (Albany NY)
Astrocyte-derived VEGF increases cerebral microvascular permeability under high salt conditions. [Abstract]2020 Jun 22;12(12):11781-11793. PMID: 32568100
Solvent & Solubility
DMSO : 100 mg/mL (35.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (17.98 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 33.33 mg/mL (11.98 mM); Clear solution; Need ultrasonic
Protocol
SN50 is diluted in distilled sterilization water to create a stock solution. The final concentration of the SN50 solution used is 18 µM. Cell viability is assessed with MTT assay. To determine the effects of SN50 on enhancing the role of LY294002 on SGC7901 cells, cells are plated into 96-well microplates (7×1000 cells/well) and cultured for 24 h. Then LY294002 (50 µM), SN50 (18 µM) and LY294002+SN50 are added to the culture medium and cell viability is assessed with MTT 24 h after drug treatment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: SN50 is prepared in saline (total volume: 1 μL, concentration: 0.1 μg/μL). SN50 is administered into the ipsilateral cerebral ventricle 10 min before TBI. After TBI, the bone flap is replaced, the scalp incision is sutured, and then mice are allowed to awaken and returned to their cages. Mice are killed at 1, 6, 12, 24, 48, and 72 h after operation. Loss of plasmalemma integrity is evaluated by intraperitoneal injection of PI 1 h before killing the animal[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sun YX, et al. Therapeutic effect of SN50, an inhibitor of nuclear factor-κB, in treatment of TBI in mice. Neurol Sci. 2013 Mar;34(3):345-55. [Content Brief]
[2]. Saika S, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005 May;166(5):1393-403. [Content Brief]
[3]. Zhao K, et al. SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Arch Med Sci. 2013 Dec 30;9(6):990-8. [Content Brief]
[4]. Chian CF, et al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.3595 mL | 1.7976 mL | 3.5952 mL | 8.9880 mL |
| 5 mM | 0.0719 mL | 0.3595 mL | 0.7190 mL | 1.7976 mL | |
| 10 mM | 0.0360 mL | 0.1798 mL | 0.3595 mL | 0.8988 mL | |
| 15 mM | 0.0240 mL | 0.1198 mL | 0.2397 mL | 0.5992 mL | |
| DMSO | 20 mM | 0.0180 mL | 0.0899 mL | 0.1798 mL | 0.4494 mL |
| 25 mM | 0.0144 mL | 0.0719 mL | 0.1438 mL | 0.3595 mL | |
| 30 mM | 0.0120 mL | 0.0599 mL | 0.1198 mL | 0.2996 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
SN50 Related Classifications
HY-P0151 Related Classifications
Powered by Bioz